ArticleAmerican journal of men's health
The Effects of Xialiqi Capsules in Regulating the Pyroptosis of Prostate Epithelial Cells Via NLRP3/Caspase-1 Pathway for the Treatment of Chronic Prostatitis.
Article in American journal of men's health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prostatitis-Related Male Infertility: From Inflammation and Dysbiosis to Sperm DNA Damage.Diagnostics (Basel, Switzerland) · 2026Review
- Advances in immunological research on male infertility.Frontiers in reproductive health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic prostatitis (CNP) is a prevalent inflammatory disorder among men. The Xialiqi capsule has been reported to alleviate the clinical symptoms of CNP patients, which may be related to its anti-inflammatory effect; yet, its exact mechanism of action remains unclear. In this study, human normal prostate epithelial cells (RWPE-2 cells) were categorized into a control group, a model group, an inhibitor group, along with high, medium, and low drug-containing serum groups (5%, 10%, and 15%, respectively). With the exception of the control group, cell pyroptosis models were created by stimulating with lipopolysaccharide (100 ng/mL) and adenosine triphosphate (5 mM). Subsequently, drug-containing serum and the NOD-like receptor 3 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.